Abstract
Despite the medical advances achieved during the last century to fight against bacteria, viruses, fungi and parasites, infectious diseases are still a major cause of death, disability, and social and economic upheaval for millions around the world. Challenges remain in countering microorganisms even where antibiotics and vaccines are available. Much remains to be learned about basic aspects of the host–pathogen relationship and the complexity of the immune response to infection. Animal models represent a powerful tool to dissect the host response to infection, as well as the pathogenesis of the microbe. One of the advantages of using animal models is that both genetic and environmental factors that may influence the course of an infection can be controlled, allowing a precise cause–effect analysis of the host–pathogen interactions. In addition, there are no real alternatives to whole animal models in the study of integrative physiology and dynamic pathophysiologic alterations. The use of animal models has also proven invaluable for testing the efficacy of experimental antimicrobial agents and their therapeutic regimes. The mouse model is the most widely used for many reasons, including its cost effectiveness, the high number of immunological reagents available for this species, and the relative ease of biocontainment. Mouse strains with specific properties such as transgenic mouse strains with gene insertion or targeted mutation (knock-out) are very effective tools for studying the role of specific genes controlling the immune response to infectious pathogens. Murine models will remain the most appropriate tool for evaluating new therapeutic strategies for the treatment of various diseases. The closer the model is adapted to the human disease, the more reliable will be the results.
In this chapter, the experimental procedures required to establish a mouse model of cutaneous and soft tissue infection are detailed. This model has provided invaluable insights into the pathogenicity of the agent for the human host.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Vinh, D. C. and Embil, J. M. (2005) Rapidly progressive soft tissue infections. Lancet Infect Dis. 5, 501–513.
Moet, G. J., Jones, R. N., Biedenbach, D. J., Stilwell, M. G., and Fritsche, T. R. (2007) Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis. 57, 7–13.
Segreti, J. (2005) Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect. 11 (suppl 3),29–35.
Bisno, A. L. and Stevens, D. L. (1996) Streptococcal infections of skin and soft tissues. N Engl J Med. 334,240–245.
Medina, E., Goldmann, O., Rohde, M., Lengeling, A., and Chhatwal, G. S. (2001) Genetic control of susceptibility to group A streptococcal infection in mice. J Infect Dis. 184, 846–852.
Reed, L. J. and Muench,H. A. (1938) A simple method of stimating fifty percent end points. Am J Hyg. 27, 493–497.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Medina, E. (2010). Murine Model of Cutaneous Infection with Streptococcus pyogenes . In: Proetzel, G., Wiles, M. (eds) Mouse Models for Drug Discovery. Methods in Molecular Biology, vol 602. Humana Press. https://doi.org/10.1007/978-1-60761-058-8_21
Download citation
DOI: https://doi.org/10.1007/978-1-60761-058-8_21
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-057-1
Online ISBN: 978-1-60761-058-8
eBook Packages: Springer Protocols